Australia markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
27.08+0.48 (+1.80%)
At close: 04:00PM EST
27.33 +0.25 (+0.92%)
After hours: 04:40PM EST

Fulgent Genetics, Inc.

4978 Santa Anita Avenue
Temple City, CA 91780
United States
626 350 0537

IndustryDiagnostics & Research
Full-time employees1,012

Key executives

NameTitlePayExercisedYear born
Mr. Ming HsiehChairman & CEO1.66MN/A1956
Mr. Jian XieCOO & President755.73kN/A1966
Mr. Paul KimChief Financial Officer757.59kN/A1967
Dr. Han Lin Gao D.A.B.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Laboratory Director630.61kN/A1967
Ms. Natalie PrescottGeneral Counsel & Chief Privacy OfficerN/AN/AN/A
Ms. Doreen NgVP of Operations & Compliance and GM of Houston OfficeN/AN/AN/A
Mr. Jakub SramVice President of Business Development & SalesN/AN/AN/A
Ms. Ellen TsuiVice President of Human ResourcesN/AN/AN/A
Mr. Brandon PerthuisChief Commercial OfficerN/AN/AN/A
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/AN/A1957
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.